AEON Biopharma Files 8-K on Shareholder Vote Matters
Ticker: AEON · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1837607
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
AEON Biopharma is holding a shareholder vote on June 13, 2025.
AI Summary
AEON Biopharma, Inc. filed an 8-K on June 13, 2025, to report on matters submitted to a vote of its security holders. The filing details the submission of specific items for shareholder approval, as required by SEC regulations. This action is a procedural step for the company, indicating a formal process for corporate decision-making involving its investors.
Why It Matters
This filing indicates that AEON Biopharma is engaging its shareholders in a formal voting process for specific corporate matters, which is a standard but important part of corporate governance.
Risk Assessment
Risk Level: low — The filing is a routine procedural disclosure regarding a shareholder vote, with no immediate financial or operational risks indicated.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- June 13, 2025 (date) — Date of report and earliest event
FAQ
What specific matters were submitted to a vote of AEON Biopharma's security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 13, 2025.
What is AEON Biopharma, Inc.'s principal executive office address?
AEON Biopharma, Inc.'s principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What was AEON Biopharma, Inc.'s former company name?
AEON Biopharma, Inc.'s former company name was Priveterra Acquisition Corp.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding AEON Biopharma, Inc. (AEON).